Find Funding Opportunities

Find Funding Opportunities

Subscribe to Find Funding OpportunitiesRSS
Filter By:
Returning 206 results

HEAL Initiative: Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed)

RFA
Thursday, March 11, 2021
Wednesday, October 11, 2023
U19
RFA-NS-21-015

Funding Opportunity Purpose

This funding opportunity announcement (FOA) is part of a suite of FOAs to support the development of safe, effective, and non-addictive therapeutics to treat pain. The goal of this FOA is to support team-based research projects to develop assays, screening and early optimization work to develop a non-addictive therapeutic to treat pain. Discovery and validation of pharmacodynamic markers efficacy and pharmacokinetic/pharmacodynamic (PK/PD) studies are also responsive. The result of the project should be to advance a hit or lead to the point where they can meet the entry criteria for RFA-NS-21-010 HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) within the 5 years of the award, there is no opportunity for renewal of this award. Applications should propose a plan that will lead to the development of analgesics with a rigorous biological rationale and scientifically sound assays. If the data does not currently exist, the proposal must include a strong plan for developing data linking the putative therapeutic target(s) to the proposed pain indication and supporting the hypothesis that altering the target activity will produce desirable outcomes for the disease. This FOA is not specific for any one or group of pain conditions. Projects to develop therapeutics for acute pain, chronic pain, painful neuropathy, musculoskeletal pain, headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, eye pain, sickle-cell pain, post-surgical pain, cancer pain, visceral pain, post stroke pain, myofascial pain, painful disorders of the orofacial region and other conditions will be considered.

HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (R34 Clinical Trial Not Allowed)

RFA
Thursday, March 11, 2021
Heal
Wednesday, October 11, 2023
R34
RFA-NS-21-016

Funding Opportunity Purpose

The goal of this funding opportunity announcement (FOA) is to solicit Initial Analgesic Development R34 applications that propose 2-year exploratory/planning awards that are expected to enable a future application for RFA-NS-21-015 HEAL Initiative: Team Research - for Initial Translational Efforts in Non-addictive Analgesic Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed). Thus, the limited scope of aims and approach of these applications are expected to establish a strong research team, feasibility, validity, or other technically qualifying results that support, enable, and/or lay the groundwork for a subsequent Team Research U19 application. These R34 awards will support the building of a research team to collect initial data and recruit additional collaborators. The proposal must include a plan for developing a strong research team, as well as a strategy to collect preliminary data linking putative therapeutic targets to the proposed pain indication and supporting the hypothesis that altering target activity will produce desirable outcomes for the disease.

HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development (U19 Clinical Trial Not Allowed)

RFA
Thursday, March 11, 2021
Heal
Wednesday, October 11, 2023
U19
RFA-NS-21-015

Funding Opportunity Purpose

This funding opportunity announcement (FOA) is part of a suite of FOAs to support the development of safe, effective, and non-addictive therapeutics to treat pain. The goal of this FOA is to support team-based research projects to develop assays, screening and early optimization work to develop a non-addictive therapeutic to treat pain. Discovery and validation of pharmacodynamic markers efficacy and pharmacokinetic/pharmacodynamic (PK/PD) studies are also responsive. The result of the project should be to advance a hit or lead to the point where they can meet the entry criteria for RFA-NS-21-010 HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) within the 5 years of the award, there is no opportunity for renewal of this award. Applications should propose a plan that will lead to the development of analgesics with a rigorous biological rationale and scientifically sound assays. If the data does not currently exist, the application must include a strong plan for developing data linking the putative therapeutic target(s) to the proposed pain indication and supporting the hypothesis that altering the target activity will produce desirable outcomes for the disease. This FOA is not specific for any one or group of pain conditions. Projects to develop therapeutics for acute pain, chronic pain, painful neuropathy, musculoskeletal pain, headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, eye pain, sickle-cell pain, post-surgical pain, cancer pain, visceral pain, post stroke pain, myofascial pain, painful disorders of the orofacial region and other conditions will be considered. Projects to develop analgesics for a combination of chronic overlapping pain conditions or for specific disease or pathological conditions will also be considered. Projects that seek to identify pain treatment targets in specific populations such as women, children, older adults, and other underrepresented groups will also be responsive to this FOA. Input from patients and caregivers on the therapeutic goals of the project is encouraged. The goal of each 5-year U19 application should be to identify candidate therapeutic(s) that will be ready to be submitted to RFA-NS-21-010 for further optimization.

BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed)

RFA
Wednesday, March 10, 2021
Saturday, June 8, 2024
R01
RFA-MH-21-135

Funding Opportunity Purpose

This is a reissue of RFA-MH-19-147. This FOA supports the development of software to visualize and analyze the data as part of programs of building the informatics infrastructure for the BRAIN Initiative. Other informatics programs include developing data standards that are needed to describe the new experiments that are being created by or used in the BRAIN Initiative ( RFA-MH-19-146 ), and creating the data infrastructures that will house the data from multiple experimental groups ( RFA-MH-19-145 ). Each of the programs is aimed at building an infrastructure that is used by a particular sub-domain of experimentalists rather than building a single all-encompassing informatics infrastructure now. Building the infrastructure one experimental area at a time will ensure that the infrastructure is immediately useful to components of the research community. As our understanding of the brain improves, it may be possible to create linkages between these various sub-domain specific informatics programs. Investigators of the informatics programs should keep that goal in mind and build for the future even though the current efforts are more limited in scope.

BRAIN Initiative: Secondary Analysis and Archiving of BRAIN Initiative Data (R01 Clinical Trial Not Allowed)

RFA
Wednesday, March 10, 2021
Friday, October 8, 2021
R01
RFA-MH-21-130

Funding Opportunity Purpose

This is a reissue of RFA-MH-20-120. This FOA invites applications that will conduct secondary analysis or data mining of existing data relevant to the BRAIN Initiative goal of understanding brain circuits. The FOA also invites applications that seek to prepare and submit existing data that are highly relevant to the BRAIN Initiative into one of the BRAIN Initiative data archives. Applications can propose to generate or test new hypotheses which would not be possible in studies of single experiments, single technologies or single laboratories, or were beyond the scope of the original studies. Applications that propose to reanalyze existing data sets using new tools or approaches are also welcome. The proposed research may involve innovative analyses of existing data or novel combination or integration of existing data sets to address new aims or explore new questions.

Notice of Special Interest (NOSI): Translation of BRAIN Initiative Technologies to the Marketplace

Notice of Special Interest
Wednesday, March 3, 2021
Saturday, January 6, 2024
NOT-MH-21-125

Funding Opportunity Purpose

This Notice of Special Interest (NOSI) encourages the translation of BRAIN Initiative technologies from academic and other non-small business research sectors to the marketplace. Small Business Concerns (SBCs) are encouraged to submit Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant applications that propose to further develop, optimize, validate and scale such technologies for commercial dissemination. Additionally, SBIR and STTR applications supporting the development and commercialization of novel technologies that fit within the mission of the BRAIN Initiative are encouraged.

Notice of Special Interest (NOSI): Availability of Administrative Supplements for Childcare Costs for Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellows

Notice of Special Interest
Monday, March 1, 2021
Monday, April 8, 2024
333
NOT-OD-21-070

Funding Opportunity Purpose

In accordance with NOT-OD-21-069 and ongoing efforts to support family-friendly work environments for the NIH-supported workforce, this Notice of Special Interest requests applications for administrative supplements to support childcare costs on NRSA-supported Fellowship awards.

NINDS Institutional Research Training Program (T32 - Clinical Trial Not Allowed)

PAR
Wednesday, February 24, 2021
Friday, May 26, 2023
T32
PAR-21-149

Funding Opportunity Purpose

The purpose of this FOA is to provide support for institutional research training programs in areas relevant to the NINDS mission. These institutional research training programs should produce well-trained neuroscientists who leave the program with the research skills and scientific knowledge to make a significant contribution to neuroscience research. Programs should be designed to enhance the breadth and depth of training in NINDS mission areas by incorporating didactic, research and career development components in the context of a defined scientific theme. Programs may support basic, clinical and/or translational research. Critical components of programs supported by this FOA include mechanisms to ensure a thorough understanding of experimental design, strong statistics and analytical skills, and skills for communicating science, both orally and in writing, to a wide variety of audiences. Regardless of theme, programs should provide opportunities and activities that will foster the development of quantitative literacy and the application of quantitative approaches to the trainees' research. NINDS institutional training programs are intended to be 1-2 years in duration and support training of one or more of the following groups: dissertation stage predoctoral students in their 3rd and/or 4th year of graduate school, postdoctoral fellows and fellowship-stage clinicians. (NINDS does not support first or second year graduate students under this PAR).

Notice of Special Interest (NOSI): Small Business Initiatives for Innovative Diagnostic Technology for Improving Outcomes for Maternal Health

Notice of Special Interest
Monday, February 22, 2021
Thursday, April 6, 2023
NOT-EB-21-001

Funding Opportunity Purpose

The purpose of this trans-NIH Notice of Special Interest (NOSI) is to inform potential applicants that the National Institute of Biomedical Imaging and Bioengineering and participating Institutes and Centers (ICs) invite SBIR/STTR applications to develop technologies or tools to quantitatively predict or indicate an increased risk for maternal morbidity and mortality (MMM). This NOSI is part of the Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE) initiative, which supports research to reduce preventable causes of maternal deaths and improve health for women before, during, and after delivery.

NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)

PA
Wednesday, February 10, 2021
Monday, January 8, 2024
R13
PA-21-151

Funding Opportunity Purpose

The purpose of the NIH Research Conference Grant (R13) is to support high quality conferences that are relevant to the public health and to the scientific mission of the participating Institutes and Centers.

Pages